Umsawasdi, T <br/><br/>
Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.  [electronic resource] 

 -  Cancer  Nov 1989 
 - 1995-2000 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/1097-0142(19891115)64:10<1995::aid-cncr2820641004>3.0.co;2-l  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Agranulocytosis--chemically induced<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cisplatin--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Heart--drug effects<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Myocardium--pathology<br/>Prospective Studies<br/>Random Allocation